Medical imaging

The AI Eye Podcast - GBT's CTO Discusses How Apollo Computer Vision Technology Augments Autonomous Driving and Has Potential in Many Domains

Retrieved on: 
Wednesday, November 23, 2022

Investorideas.com recently spoke with Danny Rittman, CTO of GBT Technologies Inc. (OTC Pink: GTCH), regarding the company's intelligent, wireless, motion detection patented computer vision technology, codenamed "Apollo."

Key Points: 
  • Investorideas.com recently spoke with Danny Rittman, CTO of GBT Technologies Inc. (OTC Pink: GTCH), regarding the company's intelligent, wireless, motion detection patented computer vision technology, codenamed "Apollo."
  • Rittman and GBT have recently been engaged in testing Apollo, using simulations, to identify obstacles on train tracks.
  • While the company's recent testing highlights its usefulness in transportation, its applicability extends to healthcare, security, and many other domains as well.
  • Rittman, however, adds that GBT's Apollo still improves on existing AI and computer vision solutions in autonomous driving.

Torrance Stem Cell Infusion and Peptide Therapy Launched By Springs Rejuvenation

Retrieved on: 
Thursday, November 17, 2022

Springs Rejuvenation, a Torrance, CA-based health clinic (404-780-5617) specializing in regenerative medicine, announces an expansion of its anti-aging stem cell treatments.

Key Points: 
  • Springs Rejuvenation's anti-aging stem cell services can help to stimulate collagen production, increase muscle mass, and improve cognitive performance.
  • The company's website describes stem cells used in the new treatment as the 'blank slates' of the cell world.
  • - an expert in stem cell and medical aesthetics - Springs Rejuvenation has been offering regenerative medicine solutions to patients since its inception in 2019.
  • Dr. Charles A Pereyra, founder of Springs Rejuvenation, says, "Our purpose at Springs Rejuvenation is to assist you in feeling your best.

To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research

Retrieved on: 
Tuesday, November 22, 2022

This joint study will attempt to develop Japan's first diagnostic workflow for mild cognitive impairment (MCI) and Alzheimer's disease (AD) that uses blood biomarkers.

Key Points: 
  • This joint study will attempt to develop Japan's first diagnostic workflow for mild cognitive impairment (MCI) and Alzheimer's disease (AD) that uses blood biomarkers.
  • Usuki City Medical Association will recruit applicants (50 years and older) who wish to participate in the study.
  • Primary care physicians affiliated with Usuki City Medical Association will perform simple cognitive function tests on applicants and select around 200 people with suspected MCI or mild dementia.
  • With this joint research, the four parties aim to establish a new diagnostic workflow for Alzheimer's disease that is based on blood biomarkers and includes primary care physicians.

Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Retrieved on: 
Monday, November 21, 2022

Additionally, other important research from the lecanemab clinical development program and Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations.

Key Points: 
  • Additionally, other important research from the lecanemab clinical development program and Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations.
  • - Clarity AD: Full results from the Phase 3 confirmatory Clarity AD clinical trial of lecanemab in patients with early AD will be presented in a scientific session on November 29 at 4:50 p.m. PT.
  • Eisai will host a live webcast of presentations in the session and can be viewed live on the investors section of the Eisai Co., Ltd. website.
  • The FDA has agreed that the results of Clarity AD can serve as the confirmatory study to verify the clinical benefit of lecanemab.

Fujitsu and Wakayama Medical University start joint trials for millimeter-wave sensor to detect falls of elderly patients

Retrieved on: 
Monday, November 21, 2022

TOKYO, Nov 21, 2022 - (JCN Newswire) - Fujitsu and Wakayama Medical University today announced the start of joint trials of a technology to support nurses and caregivers in visually monitoring patients in privacy-sensitive contexts, including hospital rooms and nursing facilities.

Key Points: 
  • TOKYO, Nov 21, 2022 - (JCN Newswire) - Fujitsu and Wakayama Medical University today announced the start of joint trials of a technology to support nurses and caregivers in visually monitoring patients in privacy-sensitive contexts, including hospital rooms and nursing facilities.
  • Fujitsu will analyze data obtained through the trials and further refine its technology based on analysis results evaluated by Wakayama Medical University, drawing on the Wakayama Medical University's knowledge from the medical field.
  • Based on these results, the two parties aim to offer a millimeter-wave sensor service for privacy-conscious monitoring to hospitals and nursing facilities in fiscal 2023.
  • In fiscal 2021, the Japan Hospital Association(2) counted a total of 290 falls per month at 18 hospitals in Japan.

American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

Retrieved on: 
Wednesday, November 16, 2022

This study met the primary endpoint and multiple key secondary endpoints, demonstrating the safety and efficacy of HTD1801 in treating PSC.

Key Points: 
  • This study met the primary endpoint and multiple key secondary endpoints, demonstrating the safety and efficacy of HTD1801 in treating PSC.
  • Data show that compared to placebo, both low and high doses of HTD1801 treatment could significantly reduce serum ALP levels.
  • In addition, HTD1801 significantly reduced alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT), further supporting the beneficial effects of HTD1801 in treating PSC.
  • The improvements in ALP we observed in this study, along with the excellent safety profile of HTD1801, are promising.

EQS-News: Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)

Retrieved on: 
Sunday, November 27, 2022

Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.

Key Points: 
  • Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.
  • The critical state is currently diagnosed by standard-of-care biomarkers when 50% of the kidney function is already lost (1).
  • PenKid addresses these pitfalls, offering an earlier and more precise determination of kidney function in acute and critical care settings (2).
  • Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study.

MD Medical Group Investments Plc: MD Medical Group opens new clinic in Yekaterinburg

Retrieved on: 
Sunday, November 27, 2022

MD Medical Group Investments Plc: MD Medical Group opens new clinic in Yekaterinburg

Key Points: 
  • MD Medical Group Investments Plc: MD Medical Group opens new clinic in Yekaterinburg
    Dissemination of a Regulatory Announcement that contains inside information in accordance with the Market Abuse Regulation (MAR), transmitted by EQS Group.
  • 18 November 2022 MD Medical Group Investments Plc (MD Medical Group, MDMG, Group or the Company; LSE and MOEX: MDMG), a leading Russian private healthcare provider, today announces the launch of a new out-patient clinic with a focus on IVF in Yekaterinburg.
  • The new clinic has been created in line with MD Medical Groups customary high standards of medical care and is fitted with world-class equipment produced by GE, Medtronic, ALscope and Olympus.
  • Today, MD Medical Group is expanding its presence and entering a new location the Sverdlovsk region, the largest and most dynamically developing region of the Ural Federal District.

EQS-News: Laser Photonics Sells First CleanTech Laser Blaster to Emerson Automation Solutions

Retrieved on: 
Sunday, November 27, 2022

Laser Photonics Corporation (NASDAQ: LASE) announced the sale of the first CleanTech Laser Blaster Cabinet to Emerson Automation Solutions.

Key Points: 
  • Laser Photonics Corporation (NASDAQ: LASE) announced the sale of the first CleanTech Laser Blaster Cabinet to Emerson Automation Solutions.
  • Wayne Tupuola, chief executive officer of Laser Photonics, commented: "This is the only CleanTech Laser Blaster Cabinet with the FDA's Center for Device and Radiological Heath (CDRH) approval.
  • The CleanTech Laser Blaster Cabinet is a self-contained, industrial laser cleaning machine.
  • Laser Photonics is a vertically-integrated manufacturer and R&D Center of Excellence for industrial laser technologies and systems.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

Retrieved on: 
Sunday, November 27, 2022

In the third quarter of 2022, we were very pleased to have strengthened our financial position with a successful private placement of up to EUR 30 million.

Key Points: 
  • In the third quarter of 2022, we were very pleased to have strengthened our financial position with a successful private placement of up to EUR 30 million.
  • Vivoryon now expects to report full data, including additional follow-up data, in the first quarter of 2024.
  • A Q&A session will follow the presentation of the third quarter results and operational progress.
  • Certain risk factors that may affect the Companys future financial results are discussed in the published annual financial statements of the Company.